Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by company leadership on February 9, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the execution of the GSK ShareReward Plan.
Important Facts for Investors
- Transaction Date: Shares were acquired on February 9, 2016.
- Share Price: 1368.63 pence per Ordinary Share.
- Participants: Ten Directors/PDMRs participated, including Sir Andrew Witty, Mr R G Connor, and Dr P J T Vallance.
- Acquisition Structure: Participants acquired shares through the personal contribution element and the matching element (GSK contribution) of the ShareReward Plan.
- Volume: Most participants acquired 9 shares under each element; Mr P C Thomson acquired 10 shares under each element.